PH12021551968A1 - Methods for treating ocular surface pain - Google Patents
Methods for treating ocular surface painInfo
- Publication number
- PH12021551968A1 PH12021551968A1 PH1/2021/551968A PH12021551968A PH12021551968A1 PH 12021551968 A1 PH12021551968 A1 PH 12021551968A1 PH 12021551968 A PH12021551968 A PH 12021551968A PH 12021551968 A1 PH12021551968 A1 PH 12021551968A1
- Authority
- PH
- Philippines
- Prior art keywords
- ocular surface
- methods
- treating ocular
- surface pain
- treating
- Prior art date
Links
- JFPXRFIBKKSHGY-UHFFFAOYSA-N 4-(7-hydroxy-4-oxo-2-propan-2-ylquinazolin-3-yl)benzonitrile Chemical compound CC(C)C1=NC2=CC(O)=CC=C2C(=O)N1C1=CC=C(C#N)C=C1 JFPXRFIBKKSHGY-UHFFFAOYSA-N 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000005111 ocular hyperemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806682P | 2019-02-15 | 2019-02-15 | |
| PCT/IB2020/051210 WO2020165838A1 (en) | 2019-02-15 | 2020-02-13 | Methods for treating ocular surface pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021551968A1 true PH12021551968A1 (en) | 2022-05-23 |
Family
ID=69740423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/551968A PH12021551968A1 (en) | 2019-02-15 | 2020-02-13 | Methods for treating ocular surface pain |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20200261456A1 (https=) |
| EP (1) | EP3923909A1 (https=) |
| JP (2) | JP7571037B2 (https=) |
| KR (1) | KR20210129677A (https=) |
| CN (1) | CN113453686B (https=) |
| AU (2) | AU2020222348B2 (https=) |
| BR (1) | BR112021015998A2 (https=) |
| CA (1) | CA3130038A1 (https=) |
| CL (1) | CL2021002152A1 (https=) |
| IL (1) | IL284629A (https=) |
| JO (1) | JOP20210217A1 (https=) |
| MX (2) | MX2021009702A (https=) |
| PH (1) | PH12021551968A1 (https=) |
| SG (1) | SG11202107260VA (https=) |
| TW (2) | TW202515576A (https=) |
| WO (1) | WO2020165838A1 (https=) |
| ZA (1) | ZA202104593B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| WO2022029656A1 (en) * | 2020-08-06 | 2022-02-10 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| CN119184616A (zh) * | 2024-09-03 | 2024-12-27 | 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) | 一种疼痛等级的测评方法及其评估系统 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| BRPI0620264A2 (pt) | 2005-12-22 | 2011-11-08 | Prolexys Pharmaceuticals Inc | quinazolonas aril-substituìdas e sua utilização |
| TW200738232A (en) | 2006-01-31 | 2007-10-16 | Alcon Mfg Ltd | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| AR067631A1 (es) | 2007-07-18 | 2009-10-21 | Novartis Ag | Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| CA2707441A1 (en) | 2008-01-09 | 2009-07-16 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2009090548A2 (en) | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| WO2009149239A1 (en) | 2008-06-04 | 2009-12-10 | Children's Medical Center Corporation | Methods of modulating angiogenesis via trpv4 |
| WO2010023512A1 (en) | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| US8349852B2 (en) * | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2316420B1 (en) | 2009-10-22 | 2014-02-26 | Consorzio Universitario Unifarm | Topical ophthalmic composition to reduce pain |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| CN102875480A (zh) | 2012-04-23 | 2013-01-16 | 中国药科大学 | 喹唑啉酮类血管抑制剂、其制备方法及其医药用途 |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| US9827225B2 (en) * | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| US10590077B2 (en) | 2016-09-20 | 2020-03-17 | Glaxosmithkline Intellectual Property Development Limited | TRPV4 antagonists |
| CN109790116B (zh) | 2016-09-20 | 2022-10-28 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Trpv4拮抗剂 |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| JP2022520410A (ja) * | 2019-02-15 | 2022-03-30 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤 |
-
2020
- 2020-02-13 SG SG11202107260VA patent/SG11202107260VA/en unknown
- 2020-02-13 PH PH1/2021/551968A patent/PH12021551968A1/en unknown
- 2020-02-13 KR KR1020217028994A patent/KR20210129677A/ko active Pending
- 2020-02-13 WO PCT/IB2020/051210 patent/WO2020165838A1/en not_active Ceased
- 2020-02-13 TW TW113123791A patent/TW202515576A/zh unknown
- 2020-02-13 JP JP2021547546A patent/JP7571037B2/ja active Active
- 2020-02-13 MX MX2021009702A patent/MX2021009702A/es unknown
- 2020-02-13 BR BR112021015998-3A patent/BR112021015998A2/pt unknown
- 2020-02-13 EP EP20708629.9A patent/EP3923909A1/en active Pending
- 2020-02-13 CA CA3130038A patent/CA3130038A1/en active Pending
- 2020-02-13 US US16/789,963 patent/US20200261456A1/en not_active Abandoned
- 2020-02-13 CN CN202080013685.7A patent/CN113453686B/zh active Active
- 2020-02-13 TW TW109104537A patent/TWI878266B/zh active
- 2020-02-13 AU AU2020222348A patent/AU2020222348B2/en active Active
-
2021
- 2021-04-08 US US17/225,290 patent/US11234982B2/en active Active
- 2021-07-01 ZA ZA2021/04593A patent/ZA202104593B/en unknown
- 2021-07-05 IL IL284629A patent/IL284629A/en unknown
- 2021-08-12 MX MX2025000353A patent/MX2025000353A/es unknown
- 2021-08-12 JO JOP/2021/0217A patent/JOP20210217A1/ar unknown
- 2021-08-13 CL CL2021002152A patent/CL2021002152A1/es unknown
-
2022
- 2022-03-08 US US17/653,982 patent/US20220193078A1/en not_active Abandoned
-
2023
- 2023-06-14 AU AU2023203716A patent/AU2023203716B2/en active Active
-
2024
- 2024-03-06 US US18/597,497 patent/US20240342174A1/en active Pending
- 2024-10-09 JP JP2024177283A patent/JP2025004186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020222348A1 (en) | 2021-08-05 |
| BR112021015998A2 (pt) | 2021-10-05 |
| ZA202104593B (en) | 2025-03-26 |
| JP2022520832A (ja) | 2022-04-01 |
| JP2025004186A (ja) | 2025-01-14 |
| IL284629A (en) | 2021-08-31 |
| US20210275529A1 (en) | 2021-09-09 |
| TW202515576A (zh) | 2025-04-16 |
| CN113453686A (zh) | 2021-09-28 |
| JP7571037B2 (ja) | 2024-10-22 |
| TW202045179A (zh) | 2020-12-16 |
| WO2020165838A9 (en) | 2021-03-18 |
| KR20210129677A (ko) | 2021-10-28 |
| AU2023203716B2 (en) | 2025-03-20 |
| US20220193078A1 (en) | 2022-06-23 |
| MX2021009702A (es) | 2021-09-14 |
| SG11202107260VA (en) | 2021-08-30 |
| US20240342174A1 (en) | 2024-10-17 |
| TWI878266B (zh) | 2025-04-01 |
| MX2025000353A (es) | 2025-02-10 |
| EP3923909A1 (en) | 2021-12-22 |
| CN113453686B (zh) | 2025-04-15 |
| US11234982B2 (en) | 2022-02-01 |
| JOP20210217A1 (ar) | 2023-01-30 |
| WO2020165838A1 (en) | 2020-08-20 |
| AU2020222348B2 (en) | 2023-03-16 |
| CL2021002152A1 (es) | 2022-04-18 |
| US20200261456A1 (en) | 2020-08-20 |
| CA3130038A1 (en) | 2020-08-20 |
| AU2023203716A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210224A1 (ar) | صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل)- بنزونيتريل | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| MX2025000353A (es) | Metodos para tratar el dolor de la superficie ocular | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| EA202090180A1 (ru) | Композиции nk1-антагониста и способы лечения депрессии | |
| EA202192047A1 (ru) | Соединения и их применение | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2023002851A (es) | Tratamiento de la enfermedad de parkinson. | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
| MX2022001413A (es) | Compuesto de pirimidina-5-carboxamida. | |
| EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
| MX2019002629A (es) | Formas cristalinas de compuestos terapéuticos y usos de los mismos. | |
| EA202191657A1 (ru) | Модуляторы экспрессии hsd17b13 | |
| EA201990712A1 (ru) | Лечение рассеянного склероза посредством chs-131 |